Although US President Donald Trump’s reciprocal tariff policy exempts pharmaceuticals with a 90-day hiatus, except for China, recent Scrip conversations with executives have found some businesses providing intermediates and finished products to the global market have already seen an impact on their shipments.
Discussions with contract development and manufacturing organizations (CDMOs), contract research organizations (CROs) and suppliers of intermediates from Japan and China at last week’s CPHI Japan meeting in Tokyo revealed some trade has been forced to stop due to the tariff situation, causing extra costs and raising
Key Takeaways
- Trump’s reciprocal tariff policies, while excluding pharmaceuticals for now, are already impacting pharma industry trade in APIs and intermediates, attendees at the recent CPHI Japan event tell Scrip